Last reviewed · How we verify
Fumaric acid esters
Fumaric acid esters, developed by University Hospital Muenster, are currently marketed for an unspecified primary indication. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The lack of detailed revenue data and key trial results poses a significant risk in assessing the drug's market performance and competitive landscape.
At a glance
| Generic name | Fumaric acid esters |
|---|---|
| Also known as | Fumaderm® initial, Fumaderm®, Fumaric acid |
| Sponsor | University Hospital Muenster |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis (PHASE4)
- PsoBest - The German Psoriasis Registry
- A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function (NA)
- APremilast After FumaRic Acid Ester Treatment
- A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment (PHASE3)
- Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1)
- Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fumaric acid esters CI brief — competitive landscape report
- Fumaric acid esters updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI